Diplomat Pharmacy offers CABOMETYX treatment for RCC

Diplomat Pharmacy mets out CABOMETYX treatment for Renal cell carcinoma inflicted on patients as approved by the Food and Drug administration. Formerly approved as a second-line therapy for enhanced RCC in 2016.

It is to be noted that RCC is a type of  Cancer in which malignant cells form in the lining of tubules of the kidney. According to the American Cancer Society, RCC  is more prevalent form of kidney cancer estimating around 90% of all kidney cancers.

Joel Saban, Diplomat president stated “In supporting patients with advanced renal cell carcinoma, we are pleased to offer CABOMETYX as a new first-line treatment option,CABOMETYX tablets offer an important new alternative for patients seeking therapy options in the first-line setting and beyond.”